Skip to content
Review Open access

Prostate imaging scoring systems: indications, interpretation, and clinical impact

Jan 2026 · BJR|Open · Vol 8 · 0 citations · 80 references
Medicine

TL;DR

A narrative review summarizes the principles, clinical applications, strengths, and limitations of the main prostate imaging scoring systems currently in use and incorporates artificial intelligence, hybrid PET/MRI, and combined clinical-genomic biomarkers, together with prospective multicenter validation, to advance precision, reproducibility, and personalization in prostate cancer imaging.

Abstract

Abstract Prostate imaging, and especially multiparametric magnetic resonance imaging (mpMRI), has become central to the diagnosis, risk stratification, treatment planning, and follow-up of prostate cancer. Its widespread adoption has driven the development of structured imaging scoring systems designed to standardize acquisition, interpretation, and reporting across diverse clinical scenarios. This narrative review summarizes the principles, clinical applications, strengths, and limitations of the main prostate imaging scoring systems currently in use. These include PI-RADS for cancer detection, PRECISE for monitoring patients on active surveillance, PI-RR for post-treatment local recurrence, PI-FAB and TARGET for assessment after focal therapy, Node-RADS for lymph node evaluation, MET-RADS-P for whole-body MRI assessment of metastatic disease, PSMA-RADS for molecular imaging interpretation, and PI-QUAL for prostate MRI quality assurance. Collectively, these systems provide a shared diagnostic language that improves inter-reader agreement, supports evidence-based decision-making, and facilitates multidisciplinary care. Despite their proven clinical impact, challenges remain, including inter-reader variability, heterogeneous MRI quality, limited access to advanced imaging, and incomplete validation of emerging tools. Future directions include the incorporation of artificial intelligence, hybrid PET/MRI, and combined clinical-genomic biomarkers, together with prospective multicenter validation, to advance precision, reproducibility, and personalization in prostate cancer imaging.

Read PDF

Similar papers

Open access Nov 2026

Risk-adapted MRI Protocols for the Detection of Clinically Significant Prostate Cancer.

Purpose To compare the diagnostic performance and clinical utility of three MRI protocols for detecting clinically significant prostate cancer (csPCa) according to prebiopsy risk. Materials and Methods This retrospective study included 390 male patients who underwent prostate multiparametric MRI (mpMRI) between January...

A. Ponsiglione, L. Cereser, M. De Martino et al. · 0 citations
Open access Oct 2026

Technical and Care-Related Determinants of Quality in Multiparametric Prostate MRI.

Background: Prostate cancer is one of the most prevalent malignancies among the male population, and multiparametric magnetic resonance imaging (mpMRI) has become a cornerstone of its diagnostic pathway, enabling improved detection and characterization of clinically significant lesions. However, the diagnostic performa...

Francesca Elia, G. Ungaro · 0 citations
Review Open access Oct 2026

Prostate cancer screening with MRI: insights from the ESUR Prostate MRI Working Group.

Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) remains controversial due to uncertain long-term benefits, overdiagnosis, and overtreatment of indolent disease. Magnetic resonance imaging (MRI) has transformed the diagnostic pathway of PCa and is increasingly explored as a screening tool. This...

G. Brembilla, E. Messina, T. Barret et al. · 0 citations
Open access Oct 2026

Risk Stratification of Prostate Imaging Reporting and Data System (PI-RADS 3) Lesions in the Peripheral and Transition Zones Using Clinical and Quantitative MRI Markers.

BACKGROUND Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions often undergo biopsy despite a low positive predictive value (< 25%) for clinically significant prostate cancer (csPCa), defined as International Society of Urological Pathology (ISUP) Grade Group ≥ 2. PURPOSE To determine whether mean apparent...

Tejinder Kaur, R. Chahine, N. Seiberlich et al. · 0 citations
Review Open access Nov 2026

Performance of PI-FAB and TARGET scoring systems in post focal therapy mpMRI surveillance.

BACKGROUND Prostate Imaging after Focal Ablation (PI-FAB) and Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET) scoring systems have been recently developed to improve detection of post-ablation recurrence of clinically significant prostate cancer (...

J. B. Mason, J. Arias, B. Kalaycıoğlu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.